Cumbo Alexander 4
4 · Climb Bio, Inc. · Filed Jun 8, 2026
Research Summary
AI-generated summary of this filing
Climb Bio Director Alexander Cumbo Receives 40,000-Share Option
What Happened
- Alexander Cumbo, a director of Climb Bio, was granted a derivative award on June 5, 2026: options covering 40,000 shares. The reported acquisition price is $0.00, indicating an equity award (option/grant) rather than an open-market purchase or sale. The filing classifies the transaction as an award/acquisition (code A).
Key Details
- Transaction date: June 5, 2026; filing date: June 8, 2026 (appears timely).
- Reported price: $0.00 (derivative award/option).
- Shares subject to the award: 40,000.
- Shares owned after transaction: Not specified in the filing.
- Vesting/other footnote: The award vests on the earlier of June 5, 2027 or immediately prior to the next annual meeting of stockholders, subject to Cumbo’s continued service (Footnote F1).
- Exhibit: Power of Attorney (Exhibit 24.1) included with the filing.
Context
- This was an option/award grant (a derivative acquisition), not an immediate stock purchase or sale. Options typically vest over time and do not represent immediately tradable shares until exercised and any restrictions lapse. Such grants are common for directors as compensation and do not by themselves indicate a buy or sell signal.
Insider Transaction Report
Form 4
Climb Bio, Inc.CLYM
Cumbo Alexander
Director
Transactions
- Award
Stock Option (Right to Buy)
[F1]2026-06-05+40,000→ 40,000 totalExercise: $10.55Exp: 2036-06-04→ Common Stock (40,000 underlying)
Footnotes (1)
- [F1]The shares subject to the option will vest on the earlier of June 5, 2027 or the date immediately prior to the date of the next annual meeting of stockholders, subject to the reporting person's continued service through such date.
Signature
Chandra Adams, as Attorney-in-Fact|2026-06-08